To explore the National Cancer Institute's investigation into ivermectin as a potential cancer treatment, influenced by public interest and political pressure.
Key Findings:
Ivermectin is primarily used as an antiparasitic drug and has gained popularity as a supposed treatment for various diseases, including cancer, particularly during the COVID-19 pandemic.
Previous studies have shown potential anticancer effects in laboratory settings, but there is no conclusive evidence for its effectiveness in humans.
Concerns exist that patients may delay effective cancer treatments in favor of ivermectin due to misinformation and the promotion of the drug by fringe medical groups.
Interpretation:
The NCI's decision to study ivermectin reflects a broader trend of public interest in alternative treatments, despite significant skepticism from the scientific community regarding its efficacy and safety, and the potential risks to patients.
Limitations:
Lack of robust evidence supporting ivermectin's effectiveness against cancer in humans.
Concerns about the potential for patients to forgo proven treatments in favor of unproven alternatives, and the diversion of funds from promising research.
Conclusion:
While the NCI is exploring ivermectin's potential, the scientific community remains cautious, emphasizing the need for rigorous research and the dangers of misinformation that could impact patient treatment decisions.
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.
